Cabaletta Bio, Inc.

CABA

Healthcare Biotechnology

EPS
+53.4%
Free cash flow
−35.7%

Quarter to June 2026, against a year earlier

1.30 0.02 +1.56%
Market cap
$280.4M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.8×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(93.20%) (156.03%) (126.98%) (101.06%)

+8 more TTM periods

ROA
(75.36%) (111.99%) (95.88%) (80.43%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(94.14%) (212.91%) (185.19%) (131.13%)
Free Cash Flow per Share
(1.02) (1.28) (1.66) (1.18)
Free Cash Flow
(153.93) (142.84) (132.31) (120.26)
Other line items

Show all line items

Columns are period end dates